TaiRx, Inc.
Clinical trials sponsored by TaiRx, Inc., explained in plain language.
TaiRx, Inc.
6580
TPEx
A Taiwanese biopharmaceutical company developing oncology and CNS drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New oral gel could tame tough tumors with fewer side effects Results expected Dec 2026 (estimated)
- New hope for advanced liver cancer: drug duo tested in phase 2 trial Results expected Dec 2026 (estimated)